Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05365646 · ClinicalTrials.gov registry record · NA
Fall Risk Assessment and Speech Intelligibility Enhancement Using In-ear Device
A NA study of Hearing Loss and Dizziness, sponsored by Stanford University.
- Recruiting
- Registry status
- NA
- Development phase
- 350
- Enrollment target
- 1
- Study location
NCT05365646: Recruiting NA study of Hearing Loss and Dizziness, sponsored by Stanford University.
NCT05365646 is a NA study of Hearing Loss and Dizziness that is actively recruiting participants, run by Stanford University. The registered enrollment target is 350 participants, below the 6,115-participant average among 58 other Hearing Loss trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05365646, a NA study of Hearing Loss and Dizziness, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- NA
- Development phase
- 350 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to develop and validate methods to use hearing aids equipped with embedded sensors and artificial intelligence to assist in the assessment of fall risk and in the implementation of interventions aimed at reducing the risk of falling, as well as to improve speech intelligibility in quiet and in background noise, track physical activity, and social engagement. The investigators hope is that the knowledge that is generated through this study will ultimately translate to the clinical setting and will help reduce the likelihood that individuals experience a fall, and improve the quality of hearing in individuals who wear hearing aids.
Primary Outcome
Participants will undergo the Centers for Disease Control and Prevention (CDC)'s STEADI (Stopping Elderly Accidents, Deaths \& Injuries) fall risk assessment with the hearing aids on. The scoring for these tests will be done by the tester, 2 independent raters, and the hearing aids. A comparison of the fall risk assessments by the testers and the hearing aids is the primary outcome measure. This outcome is assessed in Fall Risk Assessment participants only.
Conditions Studied
Interventions
- DEVICE Hearing aids equipped with motion sensing abilities
Study Locations (1)
California
- Stanford Ear Institute - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2022-05-23 |
| Est. Completion | 2026-10 |
| Phase | NA |
What NCT05365646 shows while recruiting
NCT05365646 is an interventional study that assigns participants to a tested intervention. The registered 350 participants enrollment target is mid-sized for trials with a published cap, below the 6,115-participant average among 58 other Hearing Loss trials with a reported enrollment target (94% lower).
The record links to 7 conditions, with Hearing Loss appearing as the primary indexed condition, and to 1 intervention - of which Hearing aids equipped with motion sensing abilities is the first listed.
NCT05365646 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05365646 about?
NCT05365646 is a clinical study titled "Fall Risk Assessment and Speech Intelligibility Enhancement Using In-ear Device". The purpose of this study is to develop and validate methods to use hearing aids equipped with embedded sensors and artificial intelligence to assist in the assessment of fall risk and in the implementation of interventions aimed at reducing the risk of falling, as well as to improve speech intellig...
What is the current status of trial NCT05365646?
This trial is currently recruiting. It is a NA study. The enrollment target is 350 participants. The study started on 2022-05-23. Estimated completion is 2026-10.
What conditions does trial NCT05365646 study?
This clinical trial studies the following conditions: Hearing Loss, Dizziness, Vertigo, Fall Prevention, Speech Intelligibility.
What interventions are being tested in trial NCT05365646?
The interventions under investigation include: Hearing aids equipped with motion sensing abilities (DEVICE).
Who is sponsoring clinical trial NCT05365646?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05365646 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hearing Loss
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05365646's enrollment target sits among peer trials
350 18th of 58 higher than 41 of 58 other Hearing Loss trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hearing Loss trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Improving Access and Affordability of Adult Hearing Healthcare
RECRUITING · NA
-
AI Noise Reduction in Phonak Hearing Aids
RECRUITING · NA
-
Investigation of a Device to Deliver Intra-Operative Therapeutic Hypothermia for Hearing Preservation in Cochlear Implantation
RECRUITING · NA
-
Auditory-Cognitive Training to Optimize Outcomes for Older CI Users
RECRUITING · NA
-
Innovations in Hearing Accessibility and Technology (IHAT) Study
RECRUITING · NA
-
Clinical Utility of Residual Hearing in the Cochlear Implant Ear
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00900575 · 350 participants · NA
Cervical Cancer Detection Using Optical Spectroscopy
- NCT01627821 · 350 participants · NA
Evaluation of the Jarvik 2000 Left Ventricular Assist System With Post-Auricular Connector--Destination Therapy Study
- NCT02357654 · 350 participants · Phase 4
GnRH for Luteal Support in IVF/ICSI/FET Cycles
- NCT03997370 · 350 participants · Phase 1
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI